Treatment cost guides, pricing units, package math, low-price red flags, and maintenance planning.
An evidence-based decision guide comparing FUE, FUT, and DHI hair transplant techniques, detailing real graft survival rates, ischemia times, contraindications, and…
A patient safety reference on gluteal fat grafting (BBL). Explore BBL mortality history, fat embolism anatomy, safety guidelines, ultrasound use, and how to vet a…
Lipedema diagnosis, staging, and treatment guide. Distinguish lipedema from lymphedema and obesity, compare WAL vs. tumescent liposuction, and clarify the adjunctive…
A clinical guide to breast implant removal surgery — comparing en bloc, total, and partial capsulectomy, the 2024 consensus on breast implant illness, recovery, and cost.
How the federal Sunshine Act and California AB 1278 expose manufacturer payments to dermatologists and plastic surgeons, how patients look up doctors, and what practices…
A regulatory and clinical profile analyzing Prollenium's Revanesse filler line, its single FDA PMA P160042 architecture, Thixofix cross-linking, and MAUDE safety data.
A regulatory and clinical profile analyzing Teoxane's RHA Collection, its single FDA PMA P170002 architecture, Preserved Network Technology, and post-market safety data.
A clinical evaluation of lipotropic MIC-B12 injections, examining the evidence for weight-loss claims, metabolic pathways, and safety profiles from public database…
Semaglutide's key US patent runs to late 2031 and tirzepatide's to early 2036. We read the FDA Orange Book to show when generic GLP-1 weight-loss drugs can actually…
The FDA's proposed exclusion of semaglutide and tirzepatide from the 503B Bulks List will end industrial GLP-1 compounding in 2026. A guide to legal timelines and…